8-K: Celularity Secures $1 Million Private Placement, Adjusts Warrants to Boost Capital

Celularity Inc. announced a private placement of Class A common stock and a significant adjustment to existing warrants, aiming to raise $1.035 million for working capital and general corporate purposes.

Summary

• Celularity Inc. entered into a Securities Purchase Agreement on June 23, 2025, for a private placement.
• The company will issue and sell 739,286 shares of Class A common stock at a purchase price of $1.40 per share.
• Gross proceeds from the private placement are expected to be $1,035,000, before deducting estimated offering expenses.
• As part of the transaction, the exercise price of 1,311,093 warrants held by purchasers will be revised from $11.50 per share to $2.50 per share.
• The expiration date of these warrants will be extended to June 30, 2030.
• Net proceeds from the private placement are intended for working capital and general corporate purposes.
• The closing of the private placement is anticipated to occur during the week of July 21, 2025, subject to customary closing conditions.

Sentiment

Score: 4

Explanation: While the capital raise provides necessary liquidity, the highly dilutive terms, including the low share price and significant warrant repricing, reflect a challenging financial position and are unfavorable for existing shareholders, leading to a slightly negative sentiment.

Positives

• Secured $1.035 million in gross proceeds, providing crucial working capital and funds for general corporate purposes.
• The capital raise enhances the company's liquidity and financial runway.
• The private placement was conducted with certain investors, indicating continued investor support, albeit at adjusted terms.

Negatives

• The issuance of 739,286 new shares at $1.40 per share will result in dilution for existing shareholders.
• The significant reduction in the exercise price of 1,311,093 warrants from $11.50 to $2.50 per share indicates a substantial decrease in the perceived value of the company's stock or a necessity to make the warrants more attractive to secure financing.
• The low share price of $1.40 for the private placement suggests a challenging valuation for the company.

Risks

• Future open market or derivative transactions by purchasers, including short sales, may negatively impact the market price of the company's publicly-traded securities.
• Hedging activities by purchasers could reduce the value of existing stockholders' equity interests.
• Failure to satisfy customary closing conditions could prevent the completion of the private placement.
• The company's ability to maintain its listing on Nasdaq is subject to compliance with listing and maintenance requirements.

Future Outlook

The company intends to use the net proceeds from the private placement for working capital and general corporate purposes. It also commits to timely filing of all required reports, maintaining its Nasdaq listing, and filing a registration statement on Form S-1 for the resale of the shares within 30 calendar days, aiming for effectiveness within 60 calendar days of the closing date.

Management Comments

• Robert J. Hariri, M.D., Ph.D., Chairman and CEO, signed the report on behalf of Celularity Inc.

Industry Context

This financing event is specific to Celularity Inc.'s capital needs and does not provide broader industry trends. However, for a biotechnology company, securing capital is a continuous and critical activity, often involving private placements and warrant adjustments, especially for companies in development stages or facing liquidity challenges.

Comparison to Industry Standards

• N/A The filing primarily details a specific financing transaction and does not provide performance metrics or project results that would allow for direct comparison to industry benchmarks or specific comparable companies/projects.

Stakeholder Impact

• Shareholders: Will experience dilution from the issuance of new shares and potential future dilution from the repriced warrants. The low share price and warrant adjustment may negatively impact existing share value.
• Investors (Purchasers): Gain shares at a low price and warrants with a significantly reduced exercise price, offering a more favorable entry point and potential for future gains.
• Company Operations: The capital infusion provides essential working capital, supporting ongoing operations and strategic initiatives.

Next Steps

• Closing of the Private Placement is expected during the week of July 21, 2025.
• The company will file a current report on Form 8-K, including the Transaction Documents as exhibits.
• The company will file a registration statement on Form S-1 for the resale of the shares within 30 calendar days of the agreement date.
• The company will use commercially reasonable efforts to cause the registration statement to become effective within 60 calendar days following the Closing Date.
• The company will apply to list all of the newly issued shares on Nasdaq and promptly secure their listing.

Key Dates

Recommendation

While the capital raise provides critical liquidity, the highly dilutive terms, including the low share price and significant warrant repricing, indicate underlying financial distress and will likely pressure the stock in the short to medium term. The company's ability to execute on its strategic objectives with this new capital will be key, but the current terms suggest a challenging path forward. A 'hold' recommendation is appropriate to observe how the company utilizes the funds and if it can demonstrate improved operational performance to offset the dilutive impact.

Keywords

Celularity Inc., Private Placement, Equity Financing, Warrant Adjustment, Common Stock, Capital Raise, SEC Filing, Biotechnology, Healthcare, CELU, CELUW